MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Matteo BrunelliAlessandro TafuriLuca CimaMaria Angela CerrutoMichele MilellaAndrea ZiviSebastiano ButiMelissa BersanelliGiuseppe FornariniValerio Gaetano VelloneSara Elena RebuzziGiuseppe ProcopioElena VerzoniSergio BracardaRoberto SabbatiniCinzia BaldessariAlbino EccherRodolfo PassalacquaBruno PerrucciMaria Olga GigantiMaddalena DoniniStefano PanniMarcello TucciVeronica PratiCinzia OrtegaAnna CaliòFilippo AlongiEnrico MunariGiovanni PappagalloRoberto IacovelliAlessandra MoscaCamillo PortaGuido MartignoniAlessandro AntonelliPublished in: Journal of clinical pathology (2020)
MDM2 amplification has been seen in both PD-L1 positive and negative muscle-invasive bladder UC independently from the TCGA molecular phenotypes. MDM2 and PD-L1 might be assessed in order to predict a better response to combo/single targeted therapies.